Molnupiravir for the treatment of COVID-19 in immunocompromised participants: efficacy, safety, and virology results from the phase 3 randomized, placebo-controlled MOVe-OUT trial.

Authors:
Johnson MG; Strizki JM; Brown ML; Wan H; Shamsuddin HH and 12 more

Journal:
Infection

Publication Year: 2023

DOI:
10.1007/s15010-022-01959-9

PMCID:
PMC9844162

PMID:
36648627

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Infection

Abbreviation: Infection

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Allergy and Immunology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
A case of occupational transmission of mpox.
Migaud P; Hosmann K; Drauz D and 3 more (2023) - Transparency Score: 3/6
An appeal for strengthening genomic pathogen surveillance to improve pandemic preparedness and infe…
Salzberger B; Mellmann A; Bludau A and 19 more (2023) - Transparency Score: 3/6
Antibody responses after sequential vaccination with PCV13 and PPSV23 in kidney transplant recipien…
Mülling N; van de Sand L; Völk K and 8 more (2023) - Transparency Score: 3/6
Blazing the trail for innovative tuberculosis diagnostics.
Yerlikaya S; Broger T; Isaacs C and 6 more (2023) - Transparency Score: 3/6
Blood culture-negative infective endocarditis: are we looking hard enough?
Kirk F; Vaselli NM. (2023) - Transparency Score: 3/6
View All Papers from This Journal
Transparency Score
4/6
66.7% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Declarations Conflict of interestMatthew G. Johnson, Julie M. Strizki, Michelle L. Brown, Hong Wan (at the time of study), Hala H. Shamsuddin, Angela Williams-Diaz, Jiejun Du (at the time of study), Jay A. Grobler, Amanda Paschke, and Carisa De Anda are employees of Merck & Co., Inc., Rahway, NJ, USA. Moti Ramgopal: Consulting fees: Gilead, Merck, ViiV, Janssen; Honoraria: Gilead, ViiV, Janssen. Diana F. Florescu: Grants: Merck, Regeneron, Astellas, Novavax, Bavarian Nordic, Takeda, SymBio, NobelPharma, AlloVir. Consulting fees: Takeda and Merck; Data Safety Monitoring Board/Advisory Board: Medpace. Pierre Delobel: Travel grants: BMS, Gilead, MSD, and Janssen in the last 5 years; Society: HAS/ANRS-MIE/CNS: French recommendations for treatment and prevention of HIV, hepatitis, and STIs; Scientific Committee: ANRS-MIE (CSS13). Ilsiyar Khaertynova: Nothing to disclose. José F. Flores: Nothing to disclose. Leon F. Fouche: Nothing to disclose. Shan-Chwen Chang: Nothing to disclose. Conflict of interest Matthew G. Johnson, Julie M. Strizki, Michelle L. Brown, Hong Wan (at the time of study), Hala H. Shamsuddin, Angela Williams-Diaz, Jiejun Du (at the time of study), Jay A. Grobler, Amanda Paschke, and Carisa De Anda are employees of Merck & Co., Inc., Rahway, NJ, USA. Moti Ramgopal: Consulting fees: Gilead, Merck, ViiV, Janssen; Honoraria: Gilead, ViiV, Janssen. Diana F. Florescu: Grants: Merck, Regeneron, Astellas, Novavax, Bavarian Nordic, Takeda, SymBio, NobelPharma, AlloVir. Consulting fees: Takeda and Merck; Data Safety Monitoring Board/Advisory Board: Medpace. Pierre Delobel: Travel grants: BMS, Gilead, MSD, and Janssen in the last 5 years; Society: HAS/ANRS-MIE/CNS: French recommendations for treatment and prevention of HIV, hepatitis, and STIs; Scientific Committee: ANRS-MIE (CSS13). Ilsiyar Khaertynova: Nothing to disclose. José F. Flores: Nothing to disclose. Leon F. Fouche: Nothing to disclose. Shan-Chwen Chang: Nothing to disclose."

Evidence found in paper:

"Funding This work was supported by Merck & Co., Inc., Rahway, NJ, USA."

Evidence found in paper:

"ClinicalTrials.gov Registration Number NCT04575597."

Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025